Clinical Trial Detail

NCT ID NCT00576654
Title Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

triple-receptor negative breast cancer

Hodgkin's lymphoma

non-Hodgkin lymphoma

Advanced Solid Tumor

Therapies

Irinotecan

Veliparib

Age Groups: adult senior

No variant requirements are available.